CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE is a prominent scientific journal focusing on the fields of neurology and neurosurgery, published by the esteemed Czech Medical Society. Since its inception in 1973, the journal has aimed to disseminate significant research and advancements in clinical neurology and surgery, contributing to the body of knowledge for professionals and researchers in these fields. Operating under a non-open access model, it maintains a dedicated readership interested in valuable insights from the latest studies and clinical practices. The journal is currently classified in the Q4 category in both Neurology (Clinical) and Surgery, reflecting its ongoing efforts to provide a platform for impactful research, despite being ranked in the lower percentiles within Scopus. Based in Prague, Czech Republic, this journal not only serves as a repository of clinical findings but also encourages collaboration and scholarly dialogue among neurologists and neurosurgeons, driving the field towards further innovations in patient care. With coverage extending from 1973 to 2024, it stands as a key resource for those committed to advancing neurological and surgical sciences.

PRACTICAL NEUROLOGY, published by the esteemed BMJ PUBLISHING GROUP, is a prominent journal in the fields of neurology and medicine, significantly impacting clinical practice since its inception in 2001. With an ISSN of 1474-7758 and an e-ISSN of 1474-7766, this UK-based journal reaches a diverse audience of researchers, clinicians, and students who seek to advance their understanding of neurological conditions and patient care strategies. Ranked in the second quartile (Q2) in both the miscellaneous medicine and clinical neurology categories for 2023, and positioned in the 47th percentile among its peers, PRACTICAL NEUROLOGY provides a platform for high-quality research that bridges the gap between laboratory findings and clinical applications. The journal's commitment to disseminating valuable information through peer-reviewed articles ensures that readers are equipped with the latest insights and practical knowledge necessary for improving outcomes in neurology. While access options are not currently open, the journal remains a vital resource for professionals striving to stay at the forefront of neurological research and clinical practice.

The Journal of Clinical Neurology, published by the Korean Neurological Association, is a prominent open-access journal that has been disseminating crucial findings in the field of neurology since its inception in 2008. With an ISSN of 1738-6586 and an E-ISSN of 2005-5013, this journal provides a vital platform for researchers and clinicians to share innovative research, reviews, and case studies that advance understanding and treatment of neurological disorders. The journal has established its reputation, achieving a Q3 ranking in Neurology and a Q2 ranking in Clinical Neurology in 2023, placing it among the noteworthy sources in the medical community. With its open-access format since 2011, it facilitates broad dissemination of knowledge to both the scientific community and the public, supporting the journal's mission to enhance clinical practice and promote neurological health in South Korea and beyond. As of October 2023, it holds influential Scopus ranks, reflecting its impact and relevance in the ever-evolving landscape of neuroscience. Researchers, professionals, and students alike are encouraged to contribute to and engage with the ongoing discourse by submitting their work and accessing a wealth of resources through this esteemed publication.

JAMA Neurology is a leading peer-reviewed journal published by the American Medical Association, focused on advancing the understanding and treatment of neurological disorders. With an impressive impact factor and ranked in the 99th percentile among clinical neurology journals, this publication is recognized as Q1 in its category for 2023, highlighting its significance in the field. Since its inception, the journal has provided a platform for high-quality research, clinical trials, and reviews that inform both clinicians and researchers. Operating from its headquarters in Chicago, Illinois, JAMA Neurology offers rich insights into the latest advancements in neurology, featuring articles that span a wide range of topics including neurodegenerative diseases, stroke, epilepsy, and neurocritical care. Researchers and professionals are encouraged to access the journal’s content freely, as it employs open access options to promote the dissemination of critical knowledge. As a critical resource in the field of neurology, JAMA Neurology is essential for anyone involved in this dynamic and rapidly evolving specialty.

Progress in Neurology and Psychiatry is a pivotal journal published by John Wiley & Sons Ltd, dedicated to advancing the fields of neurology and psychiatry. With a robust history dating back to its establishment, this esteemed journal holds a consistent Q3 ranking in 2023 across several categories including Neurology, Clinical Neurology, Psychiatry, and Mental Health, signifying its significant contribution to the scientific community. This journal serves as a vital source of knowledge and insight, publishing original research, reviews, and case studies that explore the intricacies of neurological and psychiatric disorders. Although it does not offer open access, the journal remains accessible to a wide audience through institutional subscriptions. By fostering a platform for scholarly discourse, Progress in Neurology and Psychiatry aims to bridge the gap between research and practice, ultimately enhancing the quality of care for individuals with neurological and psychiatric conditions. Researchers, clinicians, and students are encouraged to engage with the journal's comprehensive content to stay informed of the latest developments and emerging trends in these critical fields of medicine.

The Lancet Neurology is a premier academic journal published by Elsevier Science Inc, specializing in the field of neurology. With a robust impact factor that signifies its authoritative presence, it consistently ranks in the Q1 category for clinical neurology according to the 2023 standards, positioning itself as the leading journal in its domain, ranking #1 out of 400 in Scopus' neurology rankings and placing in the 99th percentile. Since its establishment in 2002, it has provided a vital platform for disseminating innovative research and clinical advances related to neurological disorders. The journal’s precise focus includes cutting-edge studies on neurodegenerative diseases, stroke, epilepsy, and neuroimaging, which are essential for advancing clinical practice and improving patient outcomes. While it does not offer open access, readers can find high-impact research published monthly, making it indispensable for practitioners, researchers, and students eager to stay at the forefront of neurological science.

CNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.

NEUROLOGIA, an esteemed journal published by ELSEVIER ESPANA SLU, stands at the forefront of the field of neurology, with a dedicated focus on innovative research and clinical practice since its inception in 1973. As an Open Access journal since 2017, it champions the dissemination of knowledge, allowing researchers, professionals, and students alike to access cutting-edge findings in neurology without barriers. With an impressive Scopus rank of #115 in the clinical neurology category, placing it in the 71st percentile, NEUROLOGIA is categorized as Q3 in both general medicine and clinical neurology, reflecting its impact and relevance in a rapidly evolving field. Based in Barcelona, Spain, the journal's commitment to advancing understanding of neurological conditions is underscored by its rigorous peer-review process and engagement with a global audience. As it continues to publish vital research that shapes clinical practices and informs policy, NEUROLOGIA remains an integral resource for those striving to improve outcomes in neurology.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.